OS Therapies Incorporated
OSTX
$1.79
$0.084.68%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.35M | 11.25M | 9.35M | 7.40M | 3.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.71M | 19.68M | 15.24M | 11.18M | 6.81M |
| Operating Income | -28.71M | -19.68M | -15.24M | -11.18M | -6.81M |
| Income Before Tax | -28.75M | -18.28M | -14.28M | -11.30M | -8.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.75 | -18.28 | -14.28 | -11.30 | -8.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.75M | -18.28M | -14.28M | -11.30M | -8.88M |
| EBIT | -28.71M | -19.68M | -15.24M | -11.18M | -6.81M |
| EBITDA | -28.34M | -19.44M | -15.13M | -11.18M | -6.81M |
| EPS Basic | -0.96 | -59.76 | -59.72 | -59.80 | -59.87 |
| Normalized Basic EPS | -0.60 | -37.35 | -37.33 | -37.38 | -37.41 |
| EPS Diluted | -0.96 | -59.76 | -59.72 | -59.80 | -59.87 |
| Normalized Diluted EPS | -0.60 | -37.35 | -37.33 | -37.38 | -37.41 |
| Average Basic Shares Outstanding | 113.16M | 78.37M | 62.31M | 43.19M | 27.93M |
| Average Diluted Shares Outstanding | 113.16M | 78.37M | 62.31M | 43.19M | 27.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |